Table 2.: Demographic and clinical characteristics of the RA patients, mean (95% CI) values at five year follow-up (5 year).

  Women Men
  Group 1
Mean (95% CI)
Group 2
Mean (95% CI)
P-Value Group 1
Mean (95% CI)
Group 2
Mean (95% CI)
P-Value
DAS28 5 year (0-10) 3.57 (3.46-3.68) 3.00 (2.91-3.10) <0.001 2.83 (2.67-2.98) 2.46 (2.32-2.60) 0.001
PatGA 5 year (0-100 mm) 31.1 (29.2-33.1) 31.0 (29.0-32.8) 0.899 23.5 (21.0-26.0) 22.0 (19.4-24.6) 0.310
Swollen joints 5 year (28) 3.6 (3.3-4.0) 1.7 (1.5-1.9) <0.001 2.7 (2.3-3.2) 1.2 (1.0-1.5) <0.001
Tender joints 5 year (28) 3.6 (3.3-4.0) 2.1 (1.8-2.3) <0.001 2.1 (1.7-2.5) 1.3 (1.0-1.6) 0.003
ESR 5 year (mm/h) 22.3 (20.9-23.7) 18.0 (17.0-19.1) <0.001 17.6 (15.6-19.6) 15.3 (13.5-17.0) 0.185
HAQ 5 year (0-3) 0.77 (0.71-0.82) 0.69 (0.65-0.74) 0.071 0.51 (0.45-0.58) 0.42 (0.36-0.48) 0.080
VAS pain (0-100 mm) 32.8 (30.9-34.9) 30.8 (29.0-32.7) 0.239 24.1 (21.6-26.6) 22.5 (19.9-25.1) 0.284
EULAR respons 5 year (good/moderate %) 74 87 <0.001 81 91 <0.001
Remission 5 year (%) 29 42 <0.001 52 64 0.001

* RF; rheumatoid factor, DAS; disease activity score, PatGA; patient global assessment, ESR; erythrocyte sedimentation rate, HAQ; health assessment questionnaire, VAS visual analog scale.P-values denotes the overall significance of differences between groups calculated by Kruskal-Wallis test if continuous or by Chi-square if proportions.